V C Luft1,2, B B Duncan3,4, M I Schmidt3,4, L E Chambless4,5, J S Pankow6, R C Hoogeveen7, D J Couper5, G Heiss4. 1. Graduate Studies Program in Epidemiology, Federal University of Rio Grande do Sul, Porto Alegre, Brazil. vcluft@hcpa.edu.br. 2. Food and Nutrition Research Centre, Hospital de Clínicas de Porto Alegre, Federal University of Rio Grande do Sul, Porto Alegre, Brazil. vcluft@hcpa.edu.br. 3. Graduate Studies Program in Epidemiology, Federal University of Rio Grande do Sul, Porto Alegre, Brazil. 4. Department of Epidemiology, Chapel Hill, NC, USA. 5. Department of Biostatistics, Gillings School of Global Public Health, University of North Carolina, Chapel Hill, NC, USA. 6. Division of Epidemiology & Community Health, School of Public Health, University of Minnesota, Minneapolis, MN, USA. 7. Department of Medicine, Baylor College of Medicine, Houston, TX, USA.
Abstract
AIMS: To verify whether elevated fasting levels of circulating carboxymethyl lysine (CML), an advanced glycation end product, predict the development of diabetes in middle-age adults. METHODS: Using a stratified case-cohort design, we followed 543 middle-aged individuals who developed diabetes and 514 who did not over a median 9 years in the Atherosclerosis Risk in Communities Study. Weighted Cox proportional hazards analyses were used to account for the design. RESULTS: In weighted analyses, correlation between CML levels and anthropometric, inflammatory or metabolic variables was minimal (Pearson correlations usually < 0.10). CML, when modelled as a continuous variable and after adjustment for age, sex, race, centre, parental history of diabetes, BMI, waist-to-hip ratio, non-esterified fatty acids, oxidized LDL-cholesterol, GFR, smoking, an inflammation score, adiponectin, leptin, insulin and glucose levels, was associated with an increased risk of diabetes [Hazard ratio (HR) = 1.35; 95% confidence interval (CI) 1.09-1.67, for each 100 ng/ml CML increment]. Baseline glucose level and race each modified the association (P < 0.05 for interaction), which was present only among those with impaired fasting glucose (≥ 5.6 mmol/l, HR = 1.61, 95% CI 1.26-2.05) and among white participants (HR = 1.50, 95% CI 1.13-1.99). CONCLUSIONS: Elevated fasting CML, after adjustment for multiple risk factors for diabetes, predicts the development of incident diabetes, the association being present among those with impaired fasting glucose and in white participants. These prospective findings suggest that advanced glycation end products might play a role in the development of diabetes.
AIMS: To verify whether elevated fasting levels of circulating carboxymethyl lysine (CML), an advanced glycation end product, predict the development of diabetes in middle-age adults. METHODS: Using a stratified case-cohort design, we followed 543 middle-aged individuals who developed diabetes and 514 who did not over a median 9 years in the Atherosclerosis Risk in Communities Study. Weighted Cox proportional hazards analyses were used to account for the design. RESULTS: In weighted analyses, correlation between CML levels and anthropometric, inflammatory or metabolic variables was minimal (Pearson correlations usually < 0.10). CML, when modelled as a continuous variable and after adjustment for age, sex, race, centre, parental history of diabetes, BMI, waist-to-hip ratio, non-esterified fatty acids, oxidized LDL-cholesterol, GFR, smoking, an inflammation score, adiponectin, leptin, insulin and glucose levels, was associated with an increased risk of diabetes [Hazard ratio (HR) = 1.35; 95% confidence interval (CI) 1.09-1.67, for each 100 ng/ml CML increment]. Baseline glucose level and race each modified the association (P < 0.05 for interaction), which was present only among those with impaired fasting glucose (≥ 5.6 mmol/l, HR = 1.61, 95% CI 1.26-2.05) and among white participants (HR = 1.50, 95% CI 1.13-1.99). CONCLUSIONS: Elevated fasting CML, after adjustment for multiple risk factors for diabetes, predicts the development of incident diabetes, the association being present among those with impaired fasting glucose and in white participants. These prospective findings suggest that advanced glycation end products might play a role in the development of diabetes.
Authors: Philip C Calder; Namanjeet Ahluwalia; Fred Brouns; Timo Buetler; Karine Clement; Karen Cunningham; Katherine Esposito; Lena S Jönsson; Hubert Kolb; Mirian Lansink; Ascension Marcos; Andrew Margioris; Nathan Matusheski; Herve Nordmann; John O'Brien; Giuseppe Pugliese; Salwa Rizkalla; Casper Schalkwijk; Jaakko Tuomilehto; Julia Wärnberg; Bernhard Watzl; Brigitte M Winklhofer-Roob Journal: Br J Nutr Date: 2011-12 Impact factor: 3.718
Authors: Richard D Semba; Luigi Ferrucci; Kai Sun; Justine Beck; Mansi Dalal; Ravi Varadhan; Jeremy Walston; Jack M Guralnik; Linda P Fried Journal: Aging Clin Exp Res Date: 2009-04 Impact factor: 3.636
Authors: Stephanie J Loomis; Yuan Chen; David B Sacks; Eric S Christenson; Robert H Christenson; Casey M Rebholz; Elizabeth Selvin Journal: Clin Chem Date: 2017-03-09 Impact factor: 8.327
Authors: Eric Boersma; Maxime M Vroegindewey; Victor J van den Berg; Folkert W Asselbergs; Pim van der Harst; Bas Kietselaer; Timo Lenderink; Anton J Oude Ophuis; Victor A W M Umans; Robbert J de Winter; Rohit M Oemrawsingh; K Martijn Akkerhuis Journal: Data Brief Date: 2019-11-05
Authors: Armand Ma Linkens; Alfons Jhm Houben; Petra M Niessen; Nicole Eg Wijckmans; Erica Ec de Goei; Mathias Dg Van den Eynde; Jean Ljm Scheijen; Marjo Ph van den Waarenburg; Andrea Mari; Tos Tjm Berendschot; Lukas Streese; Henner Hanssen; Martien Cjm van Dongen; Christel Cjaw van Gool; Coen DA Stehouwer; Simone Jmp Eussen; Casper G Schalkwijk Journal: JCI Insight Date: 2022-03-22
Authors: Rajkishor Nishad; Vazeeha Tahaseen; Rajesh Kavvuri; Manga Motrapu; Ashish K Singh; Kiranmayi Peddi; Anil K Pasupulati Journal: Front Med (Lausanne) Date: 2021-07-01